Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers February 19, 2018
Pharmacy Choice - Pharmaceutical News - Transition Therapeutics Announces Exercise of TT-401 Rights by Lilly - February 19, 2018

Pharmacy News Article

 7/1/13 - Transition Therapeutics Announces Exercise of TT-401 Rights by Lilly

By a News Reporter-Staff News Editor at Diabetes Week Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that Eli Lilly and Company ("Lilly") has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401. In conjunction with this assumption of rights, Transition will receive a US$7 million milestone payment (see also Pharmaceutical Companies).

Lilly and Transition have amended their agreement to address future development of TT-401 and associated financial arrangements. Lilly will assume all costs and perform all future development and commercialization activities of TT-401. Transition will contribute payment of US$14 million to Lilly in three separate installments during the Phase 2 clinical study. If TT-401 is successfully commercialized, Transition will be eligible to receive approximately US$240 million in additional milestone payments. Transition will also be eligible to receive a double-digit royalty on sales of TT-401 products and a low single digit royalty on related compounds.

"We are encouraged by the early data seen to date with TT-401, and are pleased by the efficient and thorough process by which Transition Therapeutics conducted the Phase 1 studies," said David Moller, vice president of endocrine and cardiovascular research and clinical investigation for Lilly. "We look forward to continuing the development of TT-401, as it supports our strategy of offering a broad portfolio of therapies for people with diabetes."

"We are very pleased with Lilly's commitment to the development of TT-401. The Phase 2 efficacy study and parallel product development work will be performed by Lilly's world-class clinical development team. Our additional financial contribution secures a greater vested interest for Transition, and we welcome the opportunity to invest in this drug candidate that has shown encouraging data in the recently announced human proof-of-concept study," said Dr. Tony Cruz, chairman and chief executive officer of Transition.

TT-401 is a dual agonist of the GLP-1 (Glucagon-Like Peptide-1) and glucagon receptors which is being developed to treat type 2 diabetes and accompanying obesity. In March 2010, Transition entered into a licensing and collaboration agreement with Eli Lilly and Company, where Transition acquired the rights to a series of pre-clinical compounds from Lilly, including TT-401 for the treatment of type 2 diabetes.

Keywords for this news article include: Pharmaceutical Companies, Diabetes, Investment and Finance, Transition Therapeutics Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC

(c) 2013 Diabetes Week via

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Feb 19: Acne Vulgaris: Comprehensive Pharmaceutical Care
Last Chance
Feb 20: Adult Immunizations: A Guide for Pharmacists, Techs & NPs
Feb 21: An Integrative Approach to Managing Arthritis
Feb 22: A Look Inside the Top 200 Drugs
Feb 23: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement